c-Kit

Inhibitory Selectivity

Catalog No.	Inhibitor Name	c-Kit	Other
A10290	Dasatinib	***	Abl,Src
A10468	Imatinib Mesylate	**	PDGFR,v-Abl
A10996	Cabozantinib	***	VEGFR2/KDR,c-Met,VEGFR3/FLT4
A10103	Axitinib	****	VEGFR1/FLT1,VEGFR2/Flk1,VEGFR2/KDR
A10699	Pazopanib HCl	*	VEGFR1,VEGFR2,VEGFR3
A11411	Dovitinib	****	FLT3,FGFR1,VEGFR3/FLT4
A10967	Vatalanib 2HCl	*	VEGFR2/KDR,VEGFR1/FLT1,VEGFR2/Flk1
A10558	Masitinib	*	Lyn B,PDGFRα,PDGFRβ
A10101	Tivozanib	**	VEGFR2,VEGFR3,EphB2
A10610	Amuvatinib	***	PDGFRα (V561D),FLT3 (D835Y)
A10608	Motesanib Diphosphate	***	VEGFR1,VEGFR2,VEGFR2/Flk1
A10679	OSI-930	**	FLT1,KDR,CSF-1R
A10502	Ki8751	**	VEGFR2,PDGFRα,FGFR2
A10903	Telatinib	****	VEGFR3,VEGFR2,PDGFRα
A11518	Pazopanib	*	VEGFR1,VEGFR2,VEGFR3
A10198	Dovitinib Dilactic Acid	****	FLT3,FGFR1,VEGFR3/FLT4
A16320	Dasatinib Monohydrate	***	Abl ,Src
A14156	AZD2932	***	PDGFRβ,Flt3,VEGFR-2
A10880	Sunitinib Malate		FLT3,PDGFRβ,VEGFR2
A15062	DCC-2618	***	PDGFRα, PDGFRβ
A15519	PLX647	***	Fms
A15520	Pexidartinib (PLX3397)	***	CSF-1R, Flt-3

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
Regorafenib Hydrochloride

Catalog No. A11546
Quick View

添加到收藏
VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitor

Regorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. 了解更多

Bulk Inquiry
Quick View
CHMFL-ABL/KIT-155

Catalog No. A12421
Quick View

添加到收藏
ABL/c-KIT dual kinase inhibitor

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. 了解更多

Bulk Inquiry
Quick View
c-Kit-IN-2

Catalog No. A18440
Quick View

添加到收藏
c-KIT inhibitor

c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively. 了解更多

Bulk Inquiry
Quick View
CHMFL-KIT-033

Catalog No. A18476
Quick View

添加到收藏
c-KIT T670I mutant inhibitor

CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM. 了解更多

Bulk Inquiry
Quick View
Dasatinib Monohydrate

Catalog No. A16320
Quick View

添加到收藏
Dasatinib Monohydrate是一种新型，有效且多靶点的抑制剂，靶向Abl，Src和c-Kit，IC50分别<1 nM，0.8 nM和79 nM。了解更多

Product Citations (1)

Bulk Inquiry
- Izumi-Nakaseko H, .et al. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors, Cardiovasc Toxicol, 2019, Jul 6 PMID: 31280457
Quick View
AC710 Mesylate

Catalog No. A16246
Quick View

添加到收藏
FLT3/KIT/PDGFRα/PDGFRβ 抑制剂

AC710 Mesylate是一种有效的选择性PDGFR家族激酶抑制剂，对于FLT3/KIT/PDGFRα/PDGFRβ的Kd值分别为0.6 nM/1.0 nM/1.3 nM/1.0 nM。了解更多

Bulk Inquiry
Quick View
AC710

Catalog No. A15933
Quick View

添加到收藏
FLT3/KIT/PDGFRα/PDGFRβ 抑制剂

AC710是一种有效的，具有活性的，选择性血小板衍生的生长因子受体家族激酶抑制剂，具有潜在的抗癌活性。了解更多

Bulk Inquiry
Quick View
Pexidartinib (PLX3397)

Catalog No. A15520
Quick View

添加到收藏
CSF1/Kit/FLT3 抑制剂

Pexidartinib (PLX3397)是KIT，CSF1R和FLT3的小分子酪氨酸激酶（RTK）抑制剂，具有潜在的抗肿瘤活性。了解更多

Product Citations (5)

Bulk Inquiry Free Sample
- Lu Luo, .et al. Intermittent theta-burst stimulation improves motor function by inhibiting neuronal pyroptosis and regulating microglial polarization via TLR4/NF κB/NLRP3 signaling pathway in cerebral ischemic mice, J Neuroinflammation, 2022, Jun 11;19(1):141 PMID: 35690810
- Sarah R Anderson,, .et al. Neuronal apoptosis drives remodeling states of microglia and shifts in survival pathway dependence, bioRxiv, 2022, 01.05.475126
- Hannah D Mason, .et al. Glia limitans superficialis oxidation and breakdown promotes cortical cell death after repeat head injury, JCI Insight, 2021, Oct 8;6(19):e149229 PMID: 34428178
- Chritica Lodder, .et al. CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia, Acta Neuropathol Commun, 2021, Jun 8;9(1):108 PMID: 34103079
- Anderson SR, .et al. Developmental Apoptosis Promotes a Disease-Related Gene Signature and Independence from CSF1R Signaling in Retinal Microglia, Cell Rep, 2019, May 14;27(7):2002-2013.e5 PMID: 31091440
Quick View
Masitinib mesylate

Catalog No. A15152
Quick View

添加到收藏
KIT/PDGFR 抑制剂

Masitinib mesylate是Kit和PDGFRα/β的新型抑制剂，IC50为200 nM和540 nM/800 nM，对ABL和c-Fms的抑制作用较弱。了解更多

Product Citations (1)

Bulk Inquiry
- Julia M Harrison, .et al. Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1 G93A mice, Neurobiol Dis, 2020, Aug 20;145:105052 PMID: 32827689
Quick View
Ki 20227

Catalog No. A11472
Quick View

添加到收藏
M-CSFR, CSF1R 抑制剂

Ki 20227是c-Fms酪氨酸激酶(M-CSFR,CSF1R)的抑制剂。了解更多

Product Citations (1)

Bulk Inquiry
- Wensheng Wang, .et al. Lymphatic endothelial cells produce M-CSF causing massive bone loss in mice, J Bone Miner Res, 2017, May; 32(5): 939-950 PMID: 28052488
Quick View
Pazopanib (GW-786034)

Catalog No. A11518
Quick View

添加到收藏
VEGFR 抑制剂

Pazopanib (GW-786034)是VEGFR-1，VEGFR-2，VEGFR-3，PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂，可阻止肿瘤生长并抑制血管生成。了解更多

Product Citations (3)

Bulk Inquiry Free Sample
- Koide H, .et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
- Ellawatty WEA, .et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib, Drug Metab Dispos, 2018, Jan;46(1):33-40 PMID: 29089306
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Quick View
Ki8751

Catalog No. A10502
Quick View

添加到收藏
VEGFR-2 抑制剂

ki8751是一种细胞可渗透的喹啉氧基苯基脲化合物，在基于细胞和无细胞的检测中起Flk-1 (VEGFR-2)选择性抑制剂的作用。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Kohei Ashina, .et al. VEGF-induced blood flow increase causes vascular hyper-permeability in vivo, Biochem Biophys Res Commun, 2015, Aug 21;464(2):590-5 PMID: 26163262
Quick View
Sunitinib Malate

Catalog No. A10880
Quick View

添加到收藏
RTK inhibitor

Sunitinib Malate是一种多靶点RTK抑制剂，作用于VEGFR2 (Flk-1)和 PDGFRβ，也会抑制c-Kit的活性。用于治疗肾细胞癌（RCC）和伊马替尼耐药的胃肠道间质瘤（GIST）。了解更多

Product Citations (5)

Bulk Inquiry Free Sample
- Rachel K Toth, .et al. Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28, Cells, 2022, Mar 16;11(6):1006 PMID: 35326457
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Thibaut Fourniols, .et al. Inhibition of Colorectal Cancer-Associated Fibroblasts by Lipid Nanocapsules Loaded With Acriflavine or Paclitaxel, Int J Pharm, 2020, Jun 30;584:119337 PMID: 32371002
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
Quick View
Pazopanib HCl (GW786034)

Catalog No. A10699
Quick View

添加到收藏
VEGFR/PDGFR/FGFR 抑制剂

Pazopanib HCl (GW786034)是VEGFR-1，VEGFR-2，VEGFR-3，PDGFR-a/β和c-kit的有效且选择性的多靶点酪氨酸激酶抑制剂，可阻止肿瘤生长并抑制血管生成。了解更多

Product Citations (4)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Majid Momeny, .et al. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells, Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Hideharu Yamada, .et al. lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma, Oncol Lett, 2021, Jun;21(6):455 PMID: 33907565
- Majid Momeny, .et al. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells, Eur J Pharmacol, 2020, 882:173298
Quick View
Regorafenib (BAY 73-4506)

Catalog No. A10250
Quick View

添加到收藏
VEGFR 抑制剂

Regorafenib (BAY 73-4506)是一种多激酶抑制剂，IC50为17、40和69 nM c-KIT，VEGFR2，B-Raf。Regorafenib（BAY 73-4506）是一种针对肿瘤及其脉管系统的口服生物利用型多激酶抑制剂。了解更多

Product Citations (9)

Bulk Inquiry Free Sample
- Paula Sagmeister, .et al. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis, J Hepatocell Carcinoma, 2022, Jul 9;9:595-607 PMID: 35845819
- Majid Momeny, .et al. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells, Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Jindal A, .et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma, J Transl Sci, 2020, 7: 1-10
- Makoto Koyama, .et al. Low-dose trametinib and Bcl-xL antagonist have a specific antitumor effect in KRAS-mutated colorectal cancer cells, Int J Oncol, 2020, Sep 2 PMID: 32901840
- Mariko Fujisawa, .et al. Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells, Anticancer Res, 2020, 40: 4445-4455 PMID: 32727774
- Majid Momeny, .et al. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells, Eur J Pharmacol, 2020, 882:173298
- Sunil Kumar Yadava, .et al. Low Temperature, Easy Scaling Up Method for Development of Smart Nanostructure Hybrid Lipid Capsules for Drug Delivery Application, Colloids Surf B Biointerfaces, 2020, Mar 2;190:110927 PMID: 32169777
- Takeshi Uenaka, .et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease, Hum Mol Genet, 2018, Nov 15; 27(22): 3974-3985 PMID: 30137437
- Yi Xu, .et al. Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2, Free Radic Biol Med, 2016, Jul; 96: 67-77 PMID: 27101738
Quick View
Imatinib (Gleevec)

Catalog No. A10259
Quick View

添加到收藏
PDGFR 抑制剂

Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂，抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6，0.1和0.1 μM。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Takafumi Shima, .et al. Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells, Oncol Rep, 2022, 47: 7 PMID: 34738628
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- BM Duggan, .et al. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice, Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
Quick View
Axitinib

Catalog No. A10103
Quick View

添加到收藏
VEGFR 抑制剂

Axitinib是一种小分子酪氨酸激酶抑制剂，可抑制多种靶标，包括VEGFR-1，VEGFR-2，VEGFR-3，血小板衍生生长因子受体（PDGFR）和cKIT（CD117）。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Youcef M. Rustum, .et al. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy, Int J Mol Sci, 2018, Nov; 19(11): 3378 PMID: 30380599
Quick View
XL184 free base (Cabozantinib)

Catalog No. A10996
Quick View

添加到收藏
VEGFR 抑制剂

XL184 free base (Cabozantinib)是设计用来抑制多种受体酪氨酸激酶（特别是MET和VEGFR2）的小分子。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Quick View
Imatinib Mesylate

Catalog No. A10468
Quick View

添加到收藏
Bcr-Abl 抑制剂

Imatinib mesylate是一种选择性酪氨酸激酶抑制剂，通过抑制KIT信号转导途径，在治疗胃肠间质瘤中诱导了持续的客观反应。了解更多

Product Citations (2)

Bulk Inquiry Free Sample
- Inge Govaerts, .et al. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia, J Hematol Oncol, 2021, 14: 97 PMID: 34167562
- Genevra Kuziel, .et al. Stromal CCL2 Signaling Promotes Mammary Tumor Fibrosis through Recruitment of Myeloid-Lineage Cells, Cancers (Basel), 2020, Jul 28;12(8):E2083 PMID: 32731354
Quick View
Dasatinib (BMS-354825)

Catalog No. A10290
Quick View

添加到收藏
Abl-Src 抑制剂

Dasatinib (BMS-354825)是一种口服多BCR/ABL和Src家族酪氨酸激酶抑制剂。Dasatinib (BMS-354825)的主要靶标是BCR/ABL，Src，c-Kit，ephrin受体和其他几种酪氨酸激酶，但不是erbB激酶，例如EGFR或Her2。了解更多

Product Citations (10)

Bulk Inquiry Free Sample
- Chihiro Motozono, .et al. The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition, Nat Commun, 2022, Sep 21;13(1):5440 PMID: 36130929
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- David E J Klawon, .et al. Altered selection on a single self-ligand promotes susceptibility to organ-specific T cell infiltration, J Exp Med, 2021, Jun 7;218(6) PMID: 33914024
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Sano T, .et al. Gliding Basal Cell Migration of the Urothelium during Wound Healing, Am J Pathol, 2018, Nov;188(11):2564-2573 PMID: 30121259
- Ines Peschel, .et al. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia, Haematologica, 2017, Aug; 102(8): 1378-1389 PMID: 28522571
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
- John D. Leonard, .et al. Identification of natural regulatory T cell epitopes reveals convergence on a dominant autoantigen, Immunity, 2017, Jul 18; 47(1): 107-117.e8 PMID: 28709804
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Quick View
Masitinib ( AB1010)

Catalog No. A10558
Quick View

添加到收藏
c-Kit 抑制剂

Masitinib (AB1010)是一种蛋白质酪氨酸激酶抑制剂。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- S Masson ,etc. Inhibition of Cell Signalling in Neoplastic Canine Mast Cells. , 2014, .
Quick View
Dovitinib (TKI-258)

Catalog No. A11411
Quick View

添加到收藏
RTK 抑制剂

Dovitinib是一种小分子多靶点酪氨酸激酶抑制剂，可抑制通过ZNF198-FGFR1或BCR-FGFR1转化为IL3独立性的Ba / F3细胞，IC50值分别为150 nM和90 nM。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Yunping Hu, .et al. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression, Cancer Lett, 2022, Oct 28;547:215867 PMID: 35985510
Quick View
Tivozanib (AV-951)

Catalog No. A10101
Quick View

添加到收藏
VEGFR 抑制剂

Tivozanib (AV-951)是一种口服VEGF受体酪氨酸激酶抑制剂，旨在抑制所有三种VEGF受体。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Majid Momeny, .et al. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells, Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Majid Momeny, .et al. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells, Eur J Pharmacol, 2020, 882:173298
- Majid Momeny, .et al. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells, Sci Rep, 2017, 7: 45954 PMID: 28383032
- Majid Momeny, .et al. Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells, Sci Rep, 2017, 7: 44075 PMID: 28287096
- Nicholas A. Manieri, .et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis, J Clin Invest, 2015, Sep 1; 125(9): 3606-3618 PMID: 26280574
- Usui T, .et al. Brain-derived neurotrophic factor promotes angiogenic tube formation through generation of oxidative stress in human vascular endothelial cells., Acta Physiol (Oxf), 2014, 211, 385-394 PMID: 24612679
Quick View
- 最新产品
ISCK03

Catalog No. A17162
Quick View

添加到收藏
c-kit 抑制剂

ISCK03是有效的c-kit抑制剂。了解更多

Bulk Inquiry
Quick View
AZD3229 Tosylate

Catalog No. A16867
Quick View

添加到收藏
pan-KIT mutant 抑制剂

AZD3229 Tosylate是一种有效的pan-KIT突变抑制剂，用于治疗胃肠道间质瘤。了解更多

Bulk Inquiry
Quick View
Flumatinib

Catalog No. A16258
Quick View

添加到收藏
multi-kinase 抑制剂

Flumatinib是一种多激酶抑制剂，对c-Abl，PDGFRbeta和c-Kit的IC50值分别为1.2 nM，307.6 nM和2662 nM。了解更多

Bulk Inquiry
Quick View
MP470 (MP-470, Amuvatinib)

Catalog No. A10610
Quick View

添加到收藏
RTK 抑制剂

MP470 (MP-470,Amuvatinib)是c-Kit/PDGFR酪氨酸激酶抑制剂。了解更多

Bulk Inquiry
Quick View
PLX647

Catalog No. A15519
Quick View

添加到收藏
FMS/KIT 抑制剂

PLX647是一种高度特异性的双重FMS/KIT激酶抑制剂，IC50分别为28/16 nM。了解更多

Bulk Inquiry
Quick View
AST 487

Catalog No. A15003
Quick View

添加到收藏
RET kinase 抑制剂

AST487是Ret激酶抑制剂/FLT3抑制剂，对Ret的IC50为0.88 uM。了解更多

Bulk Inquiry
Quick View
Regorafenib monohydrate

Catalog No. A15218
Quick View

添加到收藏
Tyrosine kinase 抑制剂

Regorafenib monohydrate是VEGFR1/VEGFR2/VEGFR3/PDGFRβ/Kit/RET和Raf-1的多靶点抑制剂，IC50分别为13 nM/4.2 nM/46 nM/22 nM/7 nM/1.5 nM和2.5 nM。了解更多

Bulk Inquiry
Quick View
N-Desethyl Sunitinib

Catalog No. A15182
Quick View

添加到收藏
VEGFR/PDGFRβ/KIT 抑制剂

N-Desethyl Sunitinib是舒尼替尼的主要药理活性代谢产物，是有效的，ATP竞争性VEGFR，PDGFRβ和KIT抑制剂（VEGFR -1，-2，-3的Ki值为2、9、17、8和4 nM。分别为PDGFRβ和KIT）。了解更多

Bulk Inquiry
Quick View
Vatalanib (PTK787) 2HCl

Catalog No. A10967
Quick View

添加到收藏
VEGFR 抑制剂

Vatalanib (PTK787) 2HCl是一种小分子蛋白激酶抑制剂，可抑制抑制所有已知VEGF受体以及血小板衍生的生长因子受体β和c-kit的血管生成，但对VEGFR-2的选择性最高。了解更多

Bulk Inquiry Free Sample
Quick View
DCC-2618

Catalog No. A15062
Quick View

添加到收藏
C-Kit/PDGFR 抑制剂

DCC-2618是c-Kit和PDGFR的小分子抑制剂，对c-Kit /PDGFRα/PDGFRβ的IC50分别为6 nM/30 nM/13 nM。了解更多

Bulk Inquiry
Quick View
AZD 2932

Catalog No. A14156
Quick View

添加到收藏
mutil-targeted protein tyrosine kinase 抑制剂

AZD2932是一种有效且靶向多用途的蛋白酪氨酸激酶抑制剂，对VEGFR-2，PDGFRβ，Flt-3和c-Kit的IC50分别为8 nM，4 nM，7 nM和9 nM。了解更多

Bulk Inquiry
Quick View
Flumatinib mesylate

Catalog No. A13530
Quick View

添加到收藏
c-Abl/c-Kit/PDGRFβ 抑制剂

Flumatinib mesylate以时间和剂量依赖性的方式降低U266细胞中C-MYC，HIF-1a和VEGF的表达，因此甲磺酸氟马替尼可能成为MM治疗的新药。了解更多

Bulk Inquiry
Quick View
Toceranib (PHA 291639, SU 11654)

Catalog No. A11581
Quick View

添加到收藏
c-Kit, PDGFR, VEGFR 抑制剂

Toceranib (PHA 291639,SU 11654)是一种激酶抑制剂，通过抑制KIT，血管内皮生长因子受体2和PDGFRβ同时具有抗肿瘤和抗血管生成活性。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Masaya Igase, .et al. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor, Can J Vet Res, 2016, Jan; 80(1): 21-31 PMID: 26733729
Quick View
Telatinib (BAY 57-9352)

Catalog No. A10903
Quick View

添加到收藏
VEGFR-2 抑制剂

Telatinib (BAY 57-9352)是一种口服的血管内皮生长因子受体2和3（VEGFR2/3）和血小板衍生的生长因子受体β酪氨酸激酶的小分子抑制剂，IC50分别为6 nM/4 nM，1 nM和15 nM。了解更多

Bulk Inquiry
Quick View
Dovitinib Dilactic acid (TKI258 Dilactic acid)

Catalog No. A10198
Quick View

添加到收藏
RTK 抑制剂

Dovitinib是一种小分子多靶点酪氨酸激酶抑制剂，可抑制通过ZNF198-FGFR1或BCR-FGFR1转化为IL3独立性的Ba / F3细胞，IC50值分别为150 nM和90 nM。了解更多

Bulk Inquiry
Quick View
Motesanib Diphosphate (AMG-706)

Catalog No. A10608
Quick View

添加到收藏
VEGFR 抑制剂

Motesanib也称为AMG-706，是一种有效的ATP竞争性的VEGFR1/2/3抑制剂，IC50分别为2 nM/3 nM/6 nM；对Kit具有相似的抑制活性，对VEGFR选择性比PDGFR和Ret高10倍。了解更多

Bulk Inquiry
Quick View
OSI-930

Catalog No. A10679
Quick View

添加到收藏
c-Kit/VEGFR 抑制剂

OSI-930是Kit，KDR，Flt，CSF-1R，c-Raf和Lck的有效抑制剂，IC50分别为80 nM，9 nM，8 nM，15 nM，41 nM和22 nM。了解更多

Bulk Inquiry Free Sample